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Background: During the vaccination campaigns, puppies younger than 3 months old are not targeted and remain
unvaccinated for at least the first year of their lives. Almost half of the reported rabid dogs are 6 months or
younger. Hence, we should recommend the vaccination against rabies of young puppies. Unfortunately, owing to
the exposure of puppies to infections with either canine parvovirus (CPV) or distemper virus (CDV) after the
intervention of the vaccinators, owners are reluctant to vaccinate puppies against rabies. Therefore, it is necessary
to include the CPV and CDV valences in the vaccine against rabies. Multivalent DNA-based vaccination in dogs,
including rabies and distemper valences, could help in raising vaccine coverage.
Methods: We have designed monovalent and multivalent DNA-based vaccine candidates for in vitro and in vivo
assays. These plasmids encode to the rabies virus glycoprotein and/or the canine distemper virus hemagglutinin.
The first strategy of multivalent DNA-based vaccination is by mixing plasmids encoding to a single antigen each.
The second is by simply fusing the genes of the antigens together. The third is by adding the foot and mouth
disease virus (FMDV) 2A oligopeptide gene into the antigen genes. The last strategy is by the design and use of a
bicistronic plasmid with an “Internal Ribosome Entry Site” (IRES) domain.
Results: The monovalent construct against canine distemper was efficiently validated by inducing higher humoral
immune responses compared to cell-culture-derived vaccine both in mice and dogs. All multivalent plasmids
efficiently expressed both valences after in vitro transfection of BHK-21 cells. In BALB/c mice, the bicistronic
IRES-dependant construct was the most efficient inducer of virus-neutralizing antibodies against both valences. It
was able to induce better humoral immune responses compared to the administration of either cell-culture-derived
vaccines or monovalent plasmids. The FMDV 2A was also efficient in the design of multivalent plasmids.
Conclusions: In a single shot, the design of efficient multivalent plasmids will be very beneficial for DNA-based
vaccination against numerous diseases.
Keywords: Rabies, CDV, DNA Vaccine, Multivalent, Public health, ZoonoseBackground
Rabies is a major public health concern and dogs repre-
sent the main vector and reservoir, especially in develop-
ing countries [1]. Around the world, the rabies burden is
estimated each year at around 60,000 human deaths and
more than 10 million cases of post-exposure prophylaxis
[2]. It is largely accepted that any attempt to completely
control canine rabies has to be through a strategy of* Correspondence: chokri.bahloul@pasteur.rns.tn
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reproduction in any medium, provided the ormass vaccination of dogs [3]. Such vaccination campaigns
must reach at least 70% of vaccine coverage. Several suc-
cessful programs have been conducted in South America
[4,5] and in North Africa [6]. However, even though these
programs have resulted in the control of enzootic dog ra-
bies in many urban regions, they have not been effective
in eliminating the disease in most of these countries [7,8].
Previously, we have shown that mass vaccination of
dogs against rabies in Tunisia has yielded rather subopti-
mal outcomes [9]. These can be attributable to low vac-
cination coverage rates; in many parts of the country,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the maintenance of a reservoir of rabies. In addition, in
the same work, we have recommended the vaccination
of newborn puppies in order to raise the vaccine co-
verage rates. Unfortunately, puppy owners tend to be
reluctant to vaccinate them against rabies because they
can be exposed intempestively to infections of either ca-
nine parvovirus (CPV) or canine distemper virus (CDV)
through the intervention of the vaccinators. Consequently,
we think that it is necessary to include other valences such
as CPV and CDV in the inoculated vaccine (in addition to
the rabies valence).
DNA-based vaccinations against rabies and CDV have
been largely and efficiently investigated in different ani-
mal models [10,11]. Previously, we have constructed the
plasmid pCMV3ISS-GPV which encodes to the glyco-
protein of the rabies PV strain [12]. We have shown that
a rabies post-exposure vaccination in BALB/c mice,
based on a single administration of pCMV3ISS-GPV,
is at least as effective as five-injections of cell-culture-
derived vaccine. Furthermore, we have shown that the use
of DNA-based vaccination in dogs with pCMV3ISS-GPV
is more efficient than after the use of the best commer-
cially available cell-culture-derived vaccine, under experi-
mental as well as field conditions [13].
Different strategies of multivalent DNA-based vaccin-
ation have been reported. Hence, we can design a bicis-
tronic DNA plasmid with an internal ribosome entry site
(IRES); or we can construct a plasmid encoding to a
fusion poly-protein, with or without an internal cleavage
factor, such as including the foot and mouth disease
virus (FMDV) oligopeptide 2A.
More then two decades ago, an alternative mechanism
of translation and initiation by direct ribosome binding
to the IRES domain of picornaviruses and encephalo-
myocarditis virus was reported [14,15]. Other classes of
RNA viruses (Hepatitis C Virus), or DNA viruses [16],
or even a subset of eukaryotic cells during conditions of
distress [17], are capable of following the IRES pathway.
The IRES can be used to engineer multicistronic vectors,
which may express several open frames from the same
transcript. However, it has been reported that cap-de-
pendent translation is more efficient than IRES translation
[18,19].
The large sizes of the IRES domains (~0.5 kb) and the
difficulties of ensuring a well-balanced co-expression of
multiple genes have promoted an attractive alternative
based on the FMDV oligopeptides 2A [20]. FMDV 2A
are relatively short peptides of 20 amino acids containing
the consensus motif Asp-Val/Ile-Glu-X-Asn-Pro-Gly-Pro.
During translation, the 2A interacts with the exit tunnel of
the ribosome to induce the “skipping” of the last peptide
bond at the C-terminus of 2A [21]. Then the ribosome
continues the translation downstream along the gene,after releasing the first protein fused in the C-terminus of
2A. It was already reported that the 2A peptide activities
are functional in a wide variety of eukaryotic cells derived
from yeasts, plants, and insects to mammals [22].
In order to set up a multivalent DNA-based vaccine
against rabies and canine distemper we have compared
numerous approaches in this preliminary assessment.
The first approach is by using a mixture of plasmids en-
coding to a single antigen each; the second approach is
by constructing a plasmid which encodes to a fusion of
two antigens; the third technique is similar to the previ-
ous one, but we have additionally inserted the FMDV
2A gene in frame with those of the antigens; and the last
approach consists of the cloning of a multicistronic plas-
mid which expresses a cap-dependent first antigen and
IRES-dependant second antigen. In all the constructs
the first encoded antigen is the rabies virus glycoprotein
and the second is the hemagglutinin glycoprotein of the
CDV. The expression of the encoded antigens was evi-
denced by In vitro transfection of BHK-21 cells with
the different DNA-based vaccine candidates and immuno-
histochemical identification of the corresponding antigens.
The efficiency of multivalent DNA-based vaccination was
evaluated by inoculating mice or dogs with the cor-
responding plasmids and subsequently assaying the in-
duced virus-neutralizing-antibodies against both valences.
Against the rabies virus and the CDV, neutralizing anti-
bodies highly correlate with the induced protective effects.Methods
Viruses, cells and commercial vaccines
Pasteur Virus strain (PV) for the rabies valence and the
Onderstepoort (OP-CDV) strain for the CDV valence
were used for virus-neutralizing antibody assays. VERO
cells were used for the production of OP-CDV and for
antibody seroneutralization assays against CDV. BHK-21
cells were used for the propagation of rabies PV strain,
for antibody assays using the WHO reference technique
RFFIT (Rapid Focus Fluorescent Inhibition Test) and for
in vitro expression of the different candidate DNA-based
vaccines. RabisinW (Merial, France), is an adjuvanted and
inactivated vaccine against rabies, prepared from the ra-
bies virus multiplied in NIL2 cells (established in line at
the Wistar Institute Philadelphia, USA, from a culture of
hamster embryo cells). TetradogW (Merial, France), is a
vaccine against the major canine diseases (canine dis-
temper, adenoviroses, parvovirosis, and L. canicola and
L. icterohaemorragiae leptospiroses).Plasmids
The plasmid backbone pCMV3ISS and pCMV3ISS-GPV
(Figure 1a) encoding to the PV strain glycoprotein (GPV)























Figure 1 Schematic representation of monovalent and multivalent plasmids used for DNA-based vaccination. The presented inserts are
for the constructs: a- pCMV3ISS-GPV; b- pCMV3ISS-CDVH; c- pCMV3ISS-GPV-CDVH; d- pCMV3ISS-GPV-2A-CDVH; and e-. pCMV3ISS-GPV-IRES-CDVH.
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candidate, the hemagglutinin glycoprotein gene (CDVH)
was amplified by RT-PCR using the viral RNA of the
Onderstepoort-CDV strain as a matrix and the following
set of primers:
CDVH-BglIIup : 50-AAA GAT CTA TGC TCT CCT
ACC AAA GAC AAG-30
CDVH-BamHIrev: 50-AAG GAT CCT CAG GGA TTT
GAA CGG TTA C-30
PCR product of CDVH was inserted into the plasmid
pCMV3ISS after its linearization with the restriction
endonuclease SmaI in order to obtain the candidate
DNA-based vaccine pCMV3ISS-CDVH (Figure 1b).
The construction of pCMV3ISS-GPV-CDVH, which
encodes to a fusion poly-protein of GPV and CDVH,
was obtained after the insertion of CDVH gene extrac-
ted from pCMV3ISS-CDVH by digestion with BglII and
BamHI to pCMV3ISS-GPV after linearization with BamHI
(Figure 1c).
For the construction of the candidate DNA-based vac-
cine pCMV3ISS-GPV-2A-CDVH, which encodes to a
fusion poly-protein including the GPV and CDVH with
the FMDV 2A oligopeptide in between, we have started
with the annealing of the double-stranded DNA of the
2A insert. Hence, we have designed the following set of
complimentary primers:
2Aup: 50-GAT CTA ATT TTG ACC TTC TCA AGT
TGG CGG GAG ACG TCG AGT CCA ACC CTG
GGC CC-30
2Arev: 50-GAT CCG GGC CCA GGG TTG GAC TCG
ACG TCT CCC GCC AAC TTG AGA AGG TCA
AAA TT-30
The primers were mixed in the same Eppendorf tube,
denatured for 5 minutes in boiling water and finallyannealed for 30 min at 60°C in a water bath. The resulting
double stranded DNA fragment has 50 BglII and 30 BamHI
compatible ends. This DNA fragment was inserted to
pCMV3ISS-GPV after its linearization with BamHI to give
pCMV3ISS-GPV-2A with a unique BamHI site down-
stream to the 2A gene. This construct was digested by
BamHI and inserted the CDVH gene after its extraction
from pCMV3ISS-CDVH digestion with BglII and BamHI,
to result in pCMV3ISS-GPV-2A-CDVH (Figure 1d).
The construction of pCMV3ISS-GPV-IRES-CDVH,
which is a bicistronic plasmid encoding to a cap-depend-
ant GPV and to an IRES-dependant CDVH, was conduc-
ted in different steps. The IRES sequence was amplified by
PCR using the plasmid pUMVC3-mIL12 (Aldevron, Street
South-Fargo, ND) as a matrix and the following set of
primers:
IRES-BglIIup : 50-AAA GAT CTT AAT TCC GCC
CCT CTC CCC-30
IRES-BamHIrev : 50-GGA TCC ATT ATC GTG TTT
TTC AAA GG-30
Then, the PCR product was digested by BglII and BamHI
restriction endonucleases and inserted to pCMV3ISS-GPV
after linearization with BamHI, which is upstream prior
to the stop codon of the rabies glycoprotein. The resul-
ting plasmid (pCMV3ISS-GPV-IRES) was digested with
BamHI and inserted with a CDVH gene extracted after
the digestion of pCMV3ISS-CDVH with BglII and BamHI,
and resulted in pCMV3ISS-GPV-IRES-CDVH (Figure 1e).
For plasmid purification, the Qiagen kit (Qiagen Gmbh,
Germany) was used according to manufacturer recom-
mendations.
In vitro transfection and immunofluorescent detection
For in vitro transfection in BHK-21 cells of the different
candidate DNA-based vaccines, the “SuperFect Trans-
fection Reagent” (Qiagen Gmbh, Germany) was used
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9,000 BHK-21 cells per well were incubated at 37°C
overnight in a 96-well cell culture plate. A mixture of
plasmid and the superfect reagent was incubated for
3 hours with the cells. After washing and addition of
200 μl of DMEM with 10% fetal calf serum, the cells
were incubated for 48 hours before the revealing of the
expressed proteins.
The revealing was carried out by following standard
techniques. Briefly, the cells were washed and fixed, then
incubated at 37°C for 1 h with either an anti-rabies
glycoprotein monoclonal antibody produced in mice
(HyTest Ltd, Turku, Finland), or with an anti-CDV poly-
clonal antibody produced in dogs. After washing, the
cells were further incubated at 37°C for 1 h with either a
mouse or dog anti-IgG, both FITC conjugated. Finally,
the cells were washed and observed under a fluorescent
microscope (original magnification × 400).
Inoculation of mice
BALB/c mice (IFFA credo, France) were bred in the
“Institut Pasteur de Tunis” animal facilities. Female mice
between 6 and 8 weeks old were used and were treated
according to local regulations and by a properly qualified
personnel. Each group of mice was composed of 5 ani-
mals. Before inoculation, the mice were anaesthetized
with 1.8 mg of sodium pentobarbital in 200 μl of physio-
logical water, intraperitoneally. Mice were immunized
with 50 μg of Qiagen purified plasmid of the correspon-
ding DNA vaccine candidate injected intramuscularly in
100 μl of PBS, 50 μl in each anterior tibialis muscle.
Sham vaccination consisted of a single injection of 50 μg
of Qiagen purified plasmid backbone pCMV3ISS in the
same conditions as above. Non-vaccinated control mice
received no treatment at all (PBS group). Experimental
research on mice has been performed with the approval
of the National Ethics Committee “Comité d’Ethique de
l’Institut Pasteur de Tunis”, with the reference number
“IPT/LMVBD/13/2012).
Inoculation of dogs
Two-month-old puppies from the common local mon-
grel breed were reared in a kennel in experimental con-
ditions for 4 months. They were initially deparasitized,
properly fed and at 6 months of age they were inocu-
lated the different vaccine preparations. Throughout the
experiments the animals were treated according to local
regulations and by properly qualified personnel. Three
groups of dogs were composed. The 4 dogs in the first
group were inoculated intradermally with 100 μg of the
plasmid pCMV3ISS-CDVH, by using the “Dermo-Jet In-
jector” (AKRA, France), with two shots in the inner face
of each ear. The 4 dogs in the second group were adminis-
tered subcutaneously the commercial vaccine TetradogW.The remaining 3 dogs in the third group were adminis-
tered 100 μg of the plasmid backbone pCMV3ISS in the
same conditions as with pCMV3ISS-CDVH. Blood sam-
plings were carried out at days 0, 30, 60, 90 and 365 post-
vaccination. The sera were collected and conserved at
−20°C until use for CDV-neutralizing antibody assays.
Experimental research on dogs has been performed with
the approval of the National Ethics Committee “Comité
d’Ethique de l’Institut Pasteur de Tunis”, with the refe-
rence number “IPT/LMVBD/13/2012).
Antibody assays
Assay of rabies-virus-neutralizing antibodies was carried
out by using the RFFIT technique as reported [23]. For
the assay of CDV-neutralizing antibodies, serial dilutions
of either mouse or dog sera in Dulbecco’s Minimal Es-
sential Medium (DMEM), supplemented with 10% fetal
calf serum, were prepared in a sterile 96-well tissue
culture plate. Fifty μl of CDV-Onderstepoort strain
(100 plaque-forming units per well) were added to each
well (excluding cell controls), and plates were incubated
for 1 h at 37°C. One hundred μl of a suspension contain-
ing 2.105 Vero cells were added to each well and the plates
were incubated for 4 to 6 days at 37°C. Titers were ex-
pressed as the highest dilution of sera that inhibited the
cytopathic effect of CDV-Onderstepoort strain.
Statistical analysis
EpiCalc 2000 version 1.02 was used for statistical ana-
lysis. To compare two means, a t-statistic test is used;
given the means, standard deviations and sample sizes as
determined by the Microsoft Excel Package. For rates
comparisons, two by two tables were used. Rates and
sample sizes are needed for the t-statistic tests. To calcu-
late the p-value of the t-statistic test, the method uses
the series summation. For means and rates comparisons,
p-values lower than 0.05 are significant at the 95% confi-
dence interval and higher than that are not significant.
Results
In vitro expression of monovalent and multivalent DNA-
based vaccine candidates
We have transfected BHK-21 cells with the different mo-
novalent and multivalent plasmids and revealed the ex-
pression of the encoded antigens. For the monovalent
plasmids, almost all the cells in the wells of the culture
plates have expressed the encoded proteins (Figure 2: A1
for pCMV3ISS-GPV and A2 for pCMV3ISS-CDVH).
When the transfections were with the multivalent plas-
mids, which encode to GPV and CDVH at the same
time, BHK-21 cells have expressed both antigens evenly.
Furthermore, similar to the monovalent plasmids, almost
all the cells in the corresponding wells expressed both re-







Figure 2 Cell transfection with the different DNA-based vaccine
candidates. Cells were transfected with pCMV3ISS-GPV (A1);
pCMV3ISS-CDVH (A2); pCMV3ISS-GPV and pCMV3ISS-CDVH (B1 and
2); pCMV3ISS-GPV-CDVH (C1 and 2); pCMV3ISS-GPV-2A-CDVH
(D1 and 2); pCMV3ISS-GPV-IRES-CDVH (E1 and 2); and pCMV3ISS
(F1 and 2). A-F1, were first incubated with a murine anti-rabies
glycoprotein monoclonal antibody, then with anti-IgG of mouse
conjugated with FITC. A-F2 incubated with anti-CDV polyclonal
antibodies produced in dogs, then with anti-IgG of dog FITC
conjugated. Cells were observed under a fluorescent microscope
(original magnification × 400).
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tail of plasmids (Figure 2 B1 and B2), or a plasmid which
encodes to a fusion poly-protein with or without the
FMDV 2A oligopeptide (Figure 2 C1 and C2, D1 and
D2, respectively), or a bicistronic plasmid (Figure 2 E1
and E2).
Immune responses of the monovalent DNA-based vaccine
candidate against CDV in mice and dogs
We have already shown the efficiency of DNA-based
vaccination against rabies in the mouse and dog models
[12,13]. Here we have tested the monovalent DNA-
based vaccine candidate pCMV3ISS-CDVH which enco-
des to the hemagglutinin glycoprotein of the canine
distemper virus. We have tested the capacity of this con-
struct in inducing humoral immune responses in BALB/
c mice and compared them to those generated by cell
culture based vaccination. As shown by Figure 3, at day
14 post-vaccination, none of the mice inoculated with
cell culture based vaccine (TetradogW) has developed a
detectable level of virus-neutralizing antibodies. How-
ever, out of 5 mice inoculated with pCMV3ISS-CDVH, 2
of them produced specific neutralizing antibodies higher
or equal to the threshold of 10; the mean in the group
being 5. Two weeks later, in the group TetradogW, 3
mice out of 5 had exactly the titers of 10; and in the
remaining 2, the antibodies remained undetectable (the
mean was 6). Comparatively, the mean for mice inocu-
lated with DNA was higher 40 (p-value 0.017). Further-
more, all the mice in the group developed antibody
titers greater than or equal to 20.
The humoral immune potency of the same construct
















Figure 3 CDV-neutralizing antibody titers in mice inoculated
with pCMV3ISS-CDVH or TetradogW. Groups of mice were
administered intramuscularly either 50 μg of pCMV3ISS-CDVH; or
200 μl of TetradogW and compared to sham vaccinated mice
(50 μg of pCMV3ISS) and non-vaccinated mice (PBS). All the mice
were blood-sampled two and four week’s post-vaccination. Titers
were expressed as the highest dilution of sera that inhibited the
cytopathic effect of CDV-Onderstepoort strain. Results correspond to
the mean antibody titers (the highest dilution of sera that inhibited
the cytopathic effect of CDV-Onderstepoort strain) of 5 mice per
group. Stars indicate statistical significances of differences between

















Figure 4 Kinetics of CDV-neutralizing antibody titers in dogs
inoculated pCMV3ISS-CDVH or TetradogW. Groups of 4 dogs
were administered either 100 μg of pCMV3ISS-CDVH, intradermally,
or 1 ml of TetradogW, intramuscularly and compared to a group of
3 sham-vaccinated animals (100 μg of pCMV3ISS). All the dogs were
blood-sampled at days 0, 30, 60, 90 and 365 post-vaccination. Titers
were expressed as the highest dilution of sera that inhibited the
cytopathic effect of CDV-Onderstepoort strain. Results correspond to
the mean antibody titers (the highest dilution of sera that inhibited
the cytopathic effect of CDV-Onderstepoort strain) of the
corresponding dogs in each group.
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with pCMV3ISS-CDVH oscillated between 80 and 640
with a mean of 360. At 60 and 90 days post-vaccination,
the mean titers dropped to 140 and 95, respectively. At
one year post-vaccination, each dog maintained a titer of
20. Therefore, throughout the follow up, the dogs raised
antibody titers superior to the threshold of 10, which is
considered as being protective against a CDV infection.
TetradogW subcutaneously inoculated animals showed
lower neutralizing antibody responses compared to those
inoculated pCMV3ISS-CDVH. At one month post-vac-
cination, 1 out of the 4 dogs did not seroconvert and
maintained that status during the entire observation
period. During the same period, the remaining 3 dogs
raised titers varying between 20 and 80 (mean 45). The
mean titers dropped to 10 at day 60, then to 7.5 at days
95 and 365 post-vaccination.
We can conclude that in both mice and dogs, similar to
what we have reported with rabies, DNA-based vaccin-
ation against CDV is more capable of inducing specific
neutralizing antibodies than cell-culture-derived vaccines.
Anti-rabies immune responses of multivalent DNA-based
vaccine candidates in mice
In vitro expression of the different multivalent DNA-
based vaccine candidates have shown that all the adopted
strategies are capable of efficiently expressing both enco-
ded antigens. The purpose of such constructs is a rather
efficient in vivo expression of the encoded antigens and
the induction of strong immune responses. With rabies
and CDV, the correlate of protection and the strength of
the induced immune responses are represented by the
level of production of virus-neutralizing antibodies. Wehave inoculated different groups of BALB/c mice with the
different monovalent or multivalent plasmids and assayed
in a first step their capacities to induce rabies-virus-
neutralizing antibodies. The induced antibody responses
were compared between the different groups of mice in
order to choose the more appropriate strategy to design a
multivalent plasmid. In addition, we have compared the
humoral immune responses when mice were vaccinated
with either monovalent or multivalent DNA-based vaccine
candidates, or when they were vaccinated with classical
cell culture based vaccines (RabisinW).
As shown by Figure 5, mice vaccinated with a single
dose of RabisinW developed a low level of virus-neutraliz-
ing antibodies at day 14 (1.5 IU/ml), which peaked at day
28 (4.4 IU/ml), then dropped to 1.1 IU/ml 11 months
later. When mice were inoculated with the monovalent
plasmid pCMV3ISS-GPV, slightly higher, but statistically
not significant, antibody responses were obtained with a
peak of 6.7 IU/ml at day 28 (p-value 0.348). When the
same plasmid was inoculated in mice in association with
the plasmid pCMV3ISS-CDVH, no substantial changes of
the induced responses were obtained, with a peak of
5.7 IU/ml (p-value 0.68). Therefore, we can consider that
the use of a cocktail of plasmids has neither beneficial,
nor deleterious effects in the capacity of inducing rabies-
virus-neutralizing-antibodies. The administration of either
50 μg or 100 μg of the multivalent plasmid pCMV3ISS-
GPV-CDVH induced slightly variable humoral immune
responses. The inoculation of the higher quantity of
plasmid seems to induce a higher response at day 14
(2.4 IU/ml compared to 0.7, p-value 0.1669) and very
close peaks at day 24 (6.9 IU/ml compared to 5.8, p-value
0.522), although in both cases the differences are sta-
tistically not significant. For mice inoculated with either
the plasmid pCMV3ISS-GPV-2A-CDVH or pCMV3ISS-
GPV-IRES-CDVH, the onset of the immune responses
were identical to those administered with the monovalent
plasmid (2.2 IU/ml and 2.8 IU/ml, respectively). Later on,
for both multivalent constructs, the induced rabies-virus-
neutralizing antibodies are higher than those of the mono-
valent pCMV3ISS-GPV. Therefore, mice inoculated with
the plasmid which generates GPV and CDVH after the
cleavage of the FMDV 2A oligopeptide, reached the titer
of 16.4 IU/ml (p-value 0.068) at day 28, which then
dropped to 4.1 IU/ml (p-value 0.25) at day 365. For mice
inoculated with the bicistronic plasmid pCMV3ISS-GPV-
IRES-CDVH, the mean titer was 19.4 IU/ml (p-value
0.029) at day 28, which then dropped to 5.2 IU/ml
(p-value 0.10) 11 months later.
Anti-CDV immune responses of multivalent DNA-based
vaccine candidates in mice
The same mice vaccinated with the multivalent plasmids


































































































Figure 5 Rabies-virus-neutralizing antibody titers in mice inoculated with different monovalent or multivalent DNA-based vaccine
candidates or cell-culture-derived vaccines. Groups of mice were administered intramuscularly either pCMV3ISS-GPV; or pCMV3ISS-GPV-CDVH;
or pCMV3ISS-GPV-2A-CDVH; or pCMV3ISS-GPV-IRES-CDVH, 50 μg each, or pCMV3ISS-GPV and pCMV3ISS-CDVH (50 μg, each); or pCMV3ISS-GPV-
CDVH (100 μg); or 200 μl of RabisinW and compared to sham vaccinated group (50 μg of pCMV3ISS) and non-vaccinated group (PBS). All the
mice were blood-sampled at Days 14, 28 and 365 post-vaccination. Results correspond to mean antibody titers of 5 mice per group expressed in
IU/ml of serum as measured by RFFIT. Stars indicate statistical significances of differences between groups of mice administered the multivalent
plasmid compared to those administered the monovalent plasmid pCMV3ISS-GPV.
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TetradogW or the monovalent plasmid pCMV3ISS-CDVH
(Figure 6). At day 14 post-vaccination, neither of the mice
vaccinated with TetradogW mounted any detectable level
of virus-neutralizing antibodies. At day 28, each mouse
has a titer of 10 with the mean dropping to 4 at one year
post-vaccination. Hence, cell-culture-derived anti-CDV
vaccine in mice was only capable of inducing low levels of
antibody responses. Comparatively, mice inoculated with
the monovalent plasmid, which encodes to CDVH, moun-
ted a humoral immune response (10 for each mice) at day
14 and reached a peak of 124 (p-value 0.049) two weeks
later, which then dropped to 16 (p-value 0.0046) at day
365. When the same plasmid was injected as a cocktail
with pCMV3ISS-GPV, at least the same titers were
reached post-vaccination: 16 (day 14), 152 (day 28) and 22
(day 365). Hence, the rabies valence did not show any
humoral immune inhibition effect towards the CDVH
valence, if not boosting it. The plasmid which encodes to
the fusion poly-protein (GPV-CDVH) seems to induce
slower and lower onsets of humoral immune responses
compared to the use of the monovalent plasmid, especially
at day 28 when the inoculation was with 100 μg of plas-
mid (34 p-value 0.107), but the difference is statistically
not significant. The plasmid which encodes to the fusion
of GPV-2A-CDVH showed that its capacity to induce
CDV-neutralizing antibodies was unchanged regardless
of whether the 2A oligopeptide was included in theconstruct. Hence, mice inoculated with the same quan-
tity of plasmid of either pCMV3ISS-GPV-CDVH or
pCMV3ISS-GPV-2A-CDVH, generated the same trends
of humoral immune responses. The most efficient mul-
tivalent plasmid in inducing CDV-neutralizing antibo-
dies was the bicistronic pCMV3ISS-GPV-IRES-CDVH.
It was able to onset the humoral immune responses iden-
tically to the monovalent plasmid. Furthermore, at day 28
post-vaccination, almost the same high level reached by
mice inoculated with pCMV3ISS-CDVH was obtained
after the inoculation of the multicistronic plasmid. Hence,
even though the expression of CDVH valence was IRES
dependant, the induced humoral immune responses were
equivalent to those of the monovalent plasmid.
Discussion
Rabies is still considered to be an important zoonoses in
most of the developing countries and stray dogs repre-
sent the main vector and reservoir for this disease. The
most efficient way to prevent the transmission of rabies
to humans is by vaccinating dogs. In developing coun-
tries, the turnover rate of dogs is around 30% each year,
mostly replaced by new born puppies [24]. More than
42% of the reported rabid dogs in Thailand are younger
than 6 months [8]. During the vaccination campaigns,
puppies younger than 3 months are not targeted. Owing
to the yearly recurrence of the vaccination campaigns





























































































Figure 6 CDV-neutralizing antibody titers in mice inoculated with different monovalent or multivalent DNA-based vaccine candidates
or cell-culture-derived vaccines. Groups of mice were administered intramuscularly either pCMV3ISS-CDVH; or pCMV3ISS-GPV-CDVH; or
pCMV3ISS-GPV-2A-CDVH; or pCMV3ISS-GPV-IRES-CDVH, 50 μg each, or pCMV3ISS-GPV and pCMV3ISS-CDVH (50 μg, each); or pCMV3ISS-GPV-CDVH
(100 μg); or 200 μl of TetradogW and compared to sham-vaccinated group (50 μg of pCMV3ISS) and non-vaccinated group (PBS). All the mice
were blood-sampled at Days 14, 28 and 365 post-vaccination. Titers were expressed as the highest dilution of sera that inhibited the cytopathic
effect of CDV-Onderstepoort strain. Results correspond to the mean antibody titers (the highest dilution of sera that inhibited the cytopathic
effect of CDV-Onderstepoort strain) of 5 mice per group.
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Consequently, we should persuade local populations to
vaccinate their new born puppies against rabies. Further-
more, it is well known that ownerless and stray dogs are
rarely administered a rabies vaccination. Thus, the vaccin-
ation of new born puppies before becoming ownerless
and stray dogs allows residual rabies immunity; otherwise
this will never be achieved. Unfortunately, it was well
shown that during mass vaccination of dogs against rabies,
a big proportion of the vaccinated puppies will die because
they were highly exposed to infections with either canine
parvovirus or distemper virus because of the intervention
of the vaccinators. For this reason, puppy owners are re-
luctant to vaccinate them against rabies. To overcome this
problem, we think it is necessary to include other valences
in the inoculated vaccine against rabies, especially against
CPV and CDV. We have already shown the efficiency of
DNA-based vaccination against rabies in the mouse and
dog models [12,13]. Here we have further validated a
monovalent DNA-based vaccine candidate (pCMV3ISS-
CDVH) which encodes to the hemagglutinin glycoprotein
of the canine distemper virus in the same animal models.
Hence, multivalent DNA-based vaccination in dogs, in-
cluding rabies and distemper valences, could represent a
strong argument in raising vaccine coverage and efficacy.We have designed different strategies of multivalent
DNA-based vaccination and compared their efficiencies.
The use of a cocktail of two plasmids, the first encoding
to the rabies glycoprotein, and the second to the he-
magglutinin glycoprotein of the CDV, allowed in vitro
expression and induction in mice of specific virus-neutral-
izing antibodies against both valences. The induced humo-
ral immune responses were identical to what was obtained
when the inoculation was a single monovalent plasmid.
This strategy associating two plasmids in the vaccine pre-
parations has bioprocessing drawbacks, since there is a
need for two separate processes, quality controls for each
plasmid preparation, and mixing them.
The strategy of using a plasmid, which encodes to a
fusion polyprotein without an internal cleavage element,
induced in mice the same level of neutralizing rabies
virus antibodies as the monovalent plasmid (pCMV3ISS-
GPV), whether it was administered alone or in associ-
ation with the plasmid pCMV3ISS-CDVH. Against the
CDV valence, the induced humoral immune responses
were rather depressed by the fusion of the two valences.
In both cases (against rabies and CDV), and whether
50 μg or 100 μg of the plasmid pCMV3ISS-GPV-CDVH
were inoculated to mice, the induced humoral immune
responses did not change significantly. The introduction
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not significantly improve the humoral responses against
CDV. However, it seems that when the GPV is in vivo lib-
erated from the fusion polyprotein, there is a boost of the
immune responses against the rabies virus compared to
the use of the monovalent plasmid. Hence, it can be pos-
tulated that when the CDVH native valence was expressed
in the same cell as GPV, it was able to induce a cross
boost effect. Similar results have been reported when a
mixture of antigens was used [25,26]. This can be ex-
plained by the induction of a more robust cytokine envir-
onment since it is reported that DNA-based vaccination is
highly efficient in inducing T cell responses [27].
The last strategy based on IRES multicistronic plasmid
seems to be the most efficient in inducing rabies virus and
CDV-neutralizing antibodies. The beneficial cross effect of
CDVH on rabies valence was at least the same with
pCMV3ISS-GPV-IRES-CDVH as with pCMV3ISS-GPV-
2A-CDVH. In addition, against CDV, mice inoculated
with the bicistronic plasmid raised the same level of anti-
body response as those administered the monovalent plas-
mid. Compared to mice inoculated with the cocktail of
the two monovalent plasmids (50 μg of each plasmid),
those inoculated with the bicistronic plasmid gave better
immune responses with a total quantity of 50 μg. Further-
more, it has been reported that a gene inserted upstream
from the IRES is strongly cap-dependent expressed, while
a gene placed downstream is IRES-dependent expressed
at a lower level [16,17]. Nevertheless, in our construction,
even if there is a down expression of CDVH after the in-
oculation of mice with the bicistronic plasmid, the in-
duced humoral immune responses were similar to that
after the administration of the monovalent pCMV3ISS-
CDVH plasmid. Therefore, the IRES strategy is not only
beneficial at the immunogenecity level, but also at the bio-
processiong one. This multivalent approach is based on a
single construct, allowing for a more straightforward pro-
cessing and quality control. The cost of production is fur-
ther restrained since only the half quantity of plasmid is
needed for at least the same level of immune responses.
If we compare any of the DNA-based multivalent vaccine
candidates with the use of cell culture vaccines, it is quite
clear that they are more efficient, especially against the
CDVH valence. Against the rabies valence, we have already
reported that DNA-based vaccination is superior to the in-
oculation of commercial cell culture vaccines [21,23]. With
pCMV3ISS-GPV-IRES-CDVH, the induced immune res-
ponses are further improved compared to those induced
with TetradogW (p-value 0.0008, at day 28 post-vaccination)
and RabisinW (p-value 0.013, at day 28 post-vaccination).
Conclusions
We have designed different multivalent plasmids and we
have shown that the IRES based bicistronic construct isthe most efficient. It did not only induce better humoral
immune responses in mice compared to those adminis-
tered cell-culture-derived vaccines, but also better than
after the use of monovalent plasmids. The use of FMDV
2A, inserted between the genes of two antigens, was also
efficient for the design of multivalent DNA vaccine can-
didates. Such plasmids will be very beneficial for DNA-
based vaccination against rabies in dogs. This approach
will allow the targeting in a single shot, not only against
rabies, but also against other deadly diseases of puppies,
such as canine distemper. Hence, it will efficiently contrib-
ute to the increase of the vaccination coverage against ra-
bies by persuading dog owners to include their puppies
during the national campaigns. Nevertheless, more work
is necessary to develop this kind of vaccine for final use, in
addition to including a CPV valence.
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